{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:26:30Z","timestamp":1787153190551,"version":"build-2736575974"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_6","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Reduced-dose apixaban or rivaroxaban has been suggested for extended-phase anticoagulant therapy for prevention of venous thromboembolism (VTE). The uptake of this suggestion in clinical practice is unclear. The purpose of this study was to describe the prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy in an urban university setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, single-center, observational study in patients 18 years of age or older with a history of VTE that occurred at least 6 months prior. Patients prescribed rivaroxaban or apixaban from December 2, 2021, until June 1, 2022, were included. Pregnant women and patients on apixaban or rivaroxaban for indications other than VTE were excluded. The primary outcome was the proportion of patients on reduced-dose vs full-dose apixaban or rivaroxaban. The secondary outcome was the presence of patient-specific characteristics that were more common in patients on reduced-dose vs full-dose anticoagulant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 287 patients who met the eligibility criteria, 214 (74.6%) were prescribed full-dose apixaban or rivaroxaban and 73 (25.4%) were prescribed reduced-dose apixaban or rivaroxaban. Sickle cell disease was more common in patients prescribed full-dose anticoagulant (14.5% vs 2.7%; P = 0.01), and stage 5 chronic kidney disease was more common in patients prescribed reduced-dose anticoagulant (3.3% vs 11%; P = 0.01). Prescribers specialized in hematology\/oncology were more likely to prescribe reduced-dose than full-dose anticoagulant (37.0% vs 22.4% of all prescriptions; P = 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The majority of patients were prescribed full-dose rivaroxaban or apixaban for extended-phase anticoagulation, despite guidance suggesting use of a reduced dose. Prescribers may consider patient-specific risks for thrombosis and bleeding when selecting a dose of apixaban or rivaroxaban for VTE prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag026","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:40:25Z","timestamp":1770122425000},"page":"S3007-S3017","source":"Crossref","is-referenced-by-count":0,"title":["Prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy"],"prefix":"10.1093","volume":"83","author":[{"given":"Mukti","family":"Patel","sequence":"first","affiliation":[{"name":"University of Chicago Medical Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny","family":"Mei","sequence":"additional","affiliation":[{"name":"Practice Pharmacy, UIC Retzy College of Pharmacy , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Practice Pharmacy, UIC Retzy College of Pharmacy , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M","family":"Uppuluri","sequence":"additional","affiliation":[{"name":"Practice Pharmacy, UIC Retzy College of Pharmacy , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"7","key":"2026081910412071100_zxag026-B1","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Vasanthamohan","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026081910412071100_zxag026-B2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1160\/TH13-09-0793","article-title":"Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer","volume":"112","author":"Martinez","year":"2014","journal-title":"Thromb Haemost"},{"issue":"26","key":"2026081910412071100_zxag026-B3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"2026081910412071100_zxag026-B4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2026081910412071100_zxag026-B5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2026081910412071100_zxag026-B6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"2026081910412071100_zxag026-B7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"2026081910412071100_zxag026-B8","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Witt","year":"2020","edition":"11th ed"},{"issue":"6","key":"2026081910412071100_zxag026-B9","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"7","key":"2026081910412071100_zxag026-B10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Extended Low-Intensity Anticoagulation for Thrombo-embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2026081910412071100_zxag026-B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"2026081910412071100_zxag026-B12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081910412071100_zxag026-B13","doi-asserted-by":"publisher","first-page":"e12740","DOI":"10.1002\/rth2.12740","article-title":"Physician perceptions and use of reduced-dose direct oral anticoagulants for extended-phase venous thromboembolism treatment","volume":"6","author":"Groat","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026081910412071100_zxag026-B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/jcm13010096","article-title":"Primary care clinicians\u2019 prescribing patterns of reduced-dose direct oral anticoagulants for extended-phase venous thromboembolism treatment","volume":"13","author":"Groat","year":"2024","journal-title":"J Clin Med"},{"issue":"9","key":"2026081910412071100_zxag026-B15","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jtha.2024.06.012","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: the EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2026081910412071100_zxag026-B16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"2026081910412071100_zxag026-B17","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1007\/s00277-024-06021-2","article-title":"Secondary prophylaxis of venous thromboembolism with low-dose apixaban or rivaroxaban in major-thrombophilia carriers","volume":"103","author":"Lagana","year":"2024","journal-title":"Ann Hematol"},{"issue":"10315","key":"2026081910412071100_zxag026-B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"2026081910412071100_zxag026-B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.thromres.2022.02.015","article-title":"Evaluation of standard versus reduced-dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE)","volume":"220","author":"Knueppel","year":"2022","journal-title":"Thromb Res"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag026\/66735585\/zxag026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_6\/S3007\/66735585\/zxag026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_6\/S3007\/66735585\/zxag026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:41:29Z","timestamp":1787150489000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/Supplement_6\/S3007\/8457134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":19,"journal-issue":{"issue":"Supplement_6","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag026","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,1]]},"published":{"date-parts":[[2026,2,4]]}}}